Organon Q4 Revenue Drops 5.3% to $1.51B, EPS Misses by $0.10
Organon’s Q4 CY2025 revenue fell 5.3% YoY to $1.51 billion, matching estimates, while adjusted EPS of $0.63 missed by 13.7%, lagging forecasts by $0.10. Full-year revenue guidance of $6.2 billion at midpoint tops analyst estimates by 1.5% and EBITDA guidance is $1.9 billion.
1. Q4 CY2025 Financial Results
Organon reported revenue of $1.51 billion for Q4 CY2025, down 5.3% year on year and in line with estimates, while adjusted EPS was $0.63, missing consensus by 13.7%. Adjusted EBITDA reached $383 million against projections of $390.2 million and operating margin swung to negative 9.8% from 18.1% a year earlier.
2. Full-Year Guidance Highlights
The company set full-year 2026 revenue guidance at $6.2 billion at the midpoint, representing a 1.5% upside to analyst forecasts, and projected adjusted EBITDA of $1.9 billion, reinforcing management’s push to strengthen the balance sheet and maintain financial flexibility.
3. Profitability and Margin Trends
Operating margin has deteriorated sharply as expenses rose faster than sales, pulling profitability from a 21.7% five-year average into negative territory. This decline underscores cost pressures across Organon’s women’s health therapies and established medicines portfolio.
4. Market Reaction and Outlook
Shares declined about 4.3% on the earnings release, and analysts now expect a 3.5% revenue decline in the coming year. The outlook highlights challenges in reigniting growth and improving margins amid a flat sales environment.